SCHEMBL3247954

SCHEMBL3247954

COC(=O)c1nc(N)c(Br)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
PKM P14618 2/20 0.44
RCE1 Q9Y256 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NQO2 P16083 5/20 0.40
GAA P10253 1/20 0.40
ABL1 P00519 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.37
S1PR4 O95977 1/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013864 0.85 NPSR1 (0.47) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL29756168 0.82 NPSR1 (0.44) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL30843116 0.82 NPSR1 (0.44) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL2257139 0.82 NPSR1 (0.44) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL29756239 0.81 NPSR1 (0.42) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL3243373 0.81 NPSR1 (0.42) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL29875394 0.77 ABL1 (0.45) KDM4EPKMALDH1A1NQO2GAA
SCHEMBL26918326 0.77 ABL1 (0.45) KDM4EPKMALDH1A1NQO2GAA
SCHEMBL20399637 0.75 NPSR1 (0.44) KDM4EPKMRCE1NPSR1ALDH1A1
SCHEMBL27388974 0.75 NPSR1 (0.44) KDM4EPKMRCE1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181996-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2010-05-05 EP disclosed
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US disclosed
US-7622481-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 EP disclosed
US-7312212-B2 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2007-12-25 US disclosed
EP-1399443-B1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2007-12-12 EP disclosed
US-20070135422-A1 Nitrogen-containing bicycle heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. 2007-06-14 US disclosed
US-7141564-B2 Nitrogen-containing bicyclic heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2006-11-28 US disclosed
US-20060189604-A1 Compounds GLAXO GROUP LIMITED (GB) 2006-08-24 US disclosed
US-20050159411-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2005-07-21 US disclosed
EP-1537123-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-06-08 EP disclosed
CN-1535272-A Nitrogen-containing bicyclic heterocycles ʷ 2004-10-06 CN disclosed
US-20040171620-A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-09-02 US disclosed
EP-1399443-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-24 EP disclosed
WO-2004002992-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-01-08 WO disclosed
WO-2003087098-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171620-A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials NRDC, NUCB2, NDC1 KDM4E 3867/4885PKM 4251/4885RCE1 832/4885
US-20070135422-A1 Nitrogen-containing bicycle heterocycles for use as antibacterials NRDC, NUCB2, NISCH KDM4E 4047/4885PKM 3666/4885RCE1 1214/4885
US-20060189604-A1 Compounds ELANE, PIGS, SDHA KDM4E 3723/4885PKM 2950/4885RCE1 132/4885
US-20050159411-A1 Aminopiperidine derivatives AMPD2, AMPD3, NPEPPS KDM4E 2819/4885PKM 2998/4885RCE1 2003/4885
US-20100081650-A1 Antimicrobial Compounds ELANE, NISCH, PIGS KDM4E 4273/4885PKM 4091/4885RCE1 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.